| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Priority Reports |
1 Massachusetts General Hospital Cancer Center; 2 Harvard Medical School; 3 Department of Pathology, Massachusetts General Hospital; 4 Division of Surgical Oncology, Massachusetts General Hospital and Massachusetts Eye and Ear Infirmary, Boston, Massachusetts
Requests for reprints: Leif W. Ellisen, Massachusetts General Hospital Cancer Center, GRJ-904, 55 Fruit Street, Boston, MA 02114. Phone: 617-726-4315; E-mail: lellisen{at}partners.org.
p63 is essential for normal epithelial development and is overexpressed in the vast majority of squamous cell carcinomas (SCC). Recent work had shown that
Np63
is essential for survival of SCC cells, raising the possibility that the p63 pathway may be an attractive therapeutic target in these tumors. Nevertheless, it is unknown whether a therapeutic window exists for inhibiting p63 in tumor cells versus normal epithelia. Here, we show that SCC cells are uniquely dependent on
Np63
for survival, unlike normal p63-expressing epithelial cells, and that dependence is mediated through tumor-specific up-regulation of the related protein p73. In normal primary human keratinocytes, we find that inhibition of endogenous p63 by RNA interference (RNAi) induces p21CIP1 expression, inhibits cell cycle progression, and ultimately promotes cellular senescence. In contrast, p63 inhibition in SCC cells induces proapoptotic bcl-2 family members and rapidly triggers apoptosis. Expression of p73 is low in uncultured basal keratinocytes but is markedly up-regulated in both SCC cell lines and primary tumors in vivo. Whereas p21CIP1 induction following loss of p63 in normal cells is independent of p53 and p73, both proapoptotic gene induction and cell death following p63 RNAi in tumor cells are p73 dependent. Finally, ectopic p73 expression in primary keratinocytes does not affect baseline cell proliferation but is sufficient to trigger cell death following loss of p63. Together, these findings define a specific molecular mechanism of p63 dependence through p73 up-regulation, and they provide a rationale for targeting the p63 pathway as a therapeutic strategy in SCCs. (Cancer Res 2006; 66(19): 9362-8)
This article has been cited by other articles:
![]() |
Y. Li, M. J. Peart, and C. Prives Stxbp4 Regulates {Delta}Np63 Stability by Suppression of RACK1-Dependent Degradation Mol. Cell. Biol., July 15, 2009; 29(14): 3953 - 3963. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Butler, M. B. Moore, S. R. Presnell, H.-W. Chan, N. J. Chalupny, and C. T. Lutz Proteasome Regulation of ULBP1 Transcription J. Immunol., May 15, 2009; 182(10): 6600 - 6609. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. A. Michaud, A. C. Nichols, E. A. Mroz, W. C. Faquin, J. R. Clark, S. Begum, W. H. Westra, H. Wada, P. M. Busse, L. W. Ellisen, et al. Bcl-2 Blocks Cisplatin-Induced Apoptosis and Predicts Poor Outcome Following Chemoradiation Treatment in Advanced Oropharyngeal Squamous Cell Carcinoma Clin. Cancer Res., March 1, 2009; 15(5): 1645 - 1654. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Rosenbluth, D. J. Mays, M. F. Pino, L. J. Tang, and J. A. Pietenpol A Gene Signature-Based Approach Identifies mTOR as a Regulator of p73 Mol. Cell. Biol., October 1, 2008; 28(19): 5951 - 5964. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Rosenbluth and J. A. Pietenpol The jury is in: p73 is a tumor suppressor after all Genes & Dev., October 1, 2008; 22(19): 2591 - 2595. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. E. King, R. M. Ponnamperuma, C. Allen, H. Lu, P. Duggal, Z. Chen, C. Van Waes, and W. C. Weinberg The p53 Homologue {Delta}Np63{alpha} Interacts with the Nuclear Factor-{kappa}B Pathway to Modulate Epithelial Cell Growth Cancer Res., July 1, 2008; 68(13): 5122 - 5131. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. E. Ferguson-Yates, H. Li, T. K. Dong, J. L. Hsiao, and D. H. Oh Impaired repair of cyclobutane pyrimidine dimers in human keratinocytes deficient in p53 and p63 Carcinogenesis, January 1, 2008; 29(1): 70 - 75. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |